This application is for the Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) - Data Coordinating Center. Nonalcoholic fatty liver disease (NAFLD) affects one out of every three adults and five children in North America and is a growing public health issue in the United States. NAFLD, and especially nonalcoholic steatohepatitis (NASH), may lead to end-stage liver disease and primary liver cancer, as well as liver-, cardiovascular-, and cancer-related mortality, resulting in major increases in health burdens and costs. The NASH CRN is ideally and uniquely positioned to impact the growing public health significance of NASH that can only be addressed via a large research consortium. The primary objective of the NASH CRN is to perform clinical research on NASH and NAFLD in adults and children. A closely linked and high priority secondary objective is to conduct translational research in NASH and NAFLD focusing on the pathogenesis that will provide the basis for understanding the natural history and developing means of better diagnosis, treatment, and clinical management. In the next phase of the NASH CRN, the adult and pediatric therapeutic trials initiated during the previous funding cycle will be completed, and new therapeutic trials, including phase 2a proof of mechanism and phase 2b clinical trials will be initiated, to develop evidence-based treatment options that are safe, effective, simple, and inexpensive. The longitudinal cohort of adults and children with NAFLD will be extended, which will prospectively define the natural history of the disease, the cardiovascular and metabolic risk factors, and will aid in biomarker discovery and validation, and development and validation of non-invasive techniques to evaluate and identify those with NASH/NAFLD, who will respond, and how quickly the disease is progressing. The Data Coordinating Center will provide the NASH CRN with leadership, expertise (in biostatistical analysis, study design, data management, multicenter coordination, quality control methods) and project support, communication and organization and is eager to continue its collaboration with the clinical centers, NIDDK program staff, and private sector partners to complete these very important research objectives. The NASH CRN is poised to continue its major impact on the field and directly advance the mission of the National Institutes of Health to improve the health of the public.
Nonalcoholic fatty liver disease (NAFLD) affects one in three adults and one in five children in North America. NAFLD, and especially nonalcoholic steatohepatitis (NASH), is associated with increased liver-, cardiovascular-, and cancer-related mortality. The NASH CRN aims to transform scientific discoveries from laboratory, clinical, and population studies into clinical applications to reduce the incidence and burden of adverse outcomes due to NAFLD and NASH.
|Athinarayanan, Shaminie; Wei, Rongrong; Zhang, Min et al. (2014) Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PLoS One 9:e95366|
|Molleston, Jean P; Schwimmer, Jeffrey B; Yates, Katherine P et al. (2014) Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 164:707-713.e3|
|Chen, Qing-Rong; Braun, Rosemary; Hu, Ying et al. (2013) Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One 8:e65982|
|Vos, Miriam B; Colvin, Ryan; Belt, Patricia et al. (2012) Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr 54:90-6|
|Guerrerio, Anthony L; Colvin, Ryan M; Schwartz, Amy K et al. (2012) Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 95:892-900|
|Dunn, Winston; Sanyal, Arun J; Brunt, Elizabeth M et al. (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57:384-91|
|Bambha, Kiran; Belt, Patricia; Abraham, Maria et al. (2012) Ethnicity and nonalcoholic fatty liver disease. Hepatology 55:769-80|
|Guy, Cynthia D; Suzuki, Ayako; Zdanowicz, Marzena et al. (2012) Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711-21|
|Kowdley, Kris V; Belt, Patricia; Wilson, Laura A et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55:77-85|
|Brunt, Elizabeth M; Kleiner, David E; Wilson, Laura A et al. (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810-20|
Showing the most recent 10 out of 34 publications